Demis Hassabis speaking at a technology event
June 4, 2026 Originally aired: May 26, 2026

Demis Hassabis on DeepMind's AGI Timeline, Drug Discovery, and Why the Agent-First Era Has Already Begun

In a wide-ranging conversation with Rowan Cheung, Demis Hassabis laid out why Google DeepMind's 2030 AGI target remains on schedule, what is still technically broken in today's frontier models, and why drug discovery — not consumer chat — is where artificial intelligence will deliver its most lasting proof of value.

The 2030 Window Was Never a Guess

When DeepMind was founded in 2010, Hassabis and co-founder Shane Legg mapped out a 20-year roadmap to AGI. That roadmap placed the target at 2030 — a claim that most of the field dismissed at the time. Hassabis's position now is that the estimate hasn't moved, but the confidence interval around it has narrowed dramatically. The current working window is 2029 to 2031. What has changed is not the destination but the certainty of arrival: the hard problems are understood, the research directions are active, and the compounding is visible in ways it simply wasn't a decade ago.

Jagged Intelligence and What's Still Broken

Hassabis is precise about the limits of today's systems. Current frontier models display what he calls "jagged intelligence" — extraordinary competence in some domains sitting alongside fundamental failures in others. He identifies three specific research bottlenecks that require distinct scientific breakthroughs before AGI can be responsibly claimed: true structural consistency across contexts, continuous real-time learning without catastrophic forgetting, and genuine long-term planning and abstract reasoning. These are not engineering problems that additional compute will dissolve. Each requires a conceptual advance of its own, and none has been solved.

Drug Discovery as the Real Test

The most concrete proof point Hassabis offers isn't a chatbot benchmark — it's Isomorphic Labs, DeepMind's dedicated molecular biology entity. The stated engineering target is compressing the standard ten-year drug discovery pipeline down to a matter of weeks, with initial focus on oncology and immunology. Specialised test compounds have already progressed to the pre-clinical stage. Hassabis estimates that completing a full end-to-end platform will require roughly half a dozen to a dozen additional breakthroughs of comparable magnitude to AlphaFold. The downstream clinical trial pipeline — five to ten years of biological validation — remains a physical constraint that AI can optimise but cannot bypass.

The Agent-First Architecture Overhaul

Across Google's consumer and enterprise stack, Hassabis describes a ground-up architectural rewrite moving from AI-first through model-first toward what he calls agent-first. The challenge is operational as much as technical: refactoring the entire infrastructure to support a real-time, autonomous execution loop must be executed without introducing latency or downtime for systems serving billions of daily users. The same agentic capabilities that make systems genuinely useful also expand the attack surface for adversarial exploitation — a cybersecurity dimension Hassabis treats as significantly underdiscussed relative to its actual risk, and one that he argues should be driving urgent work on international defensive standards.

What Stays Human

As the marginal cost of technical execution approaches zero, Hassabis argues that economic and creative value migrates upward — from syntax to direction, from skill to judgment. The differentiator in a world of cheap intelligence is taste, cross-domain synthesis, and the ability to ask the right questions. The caveat he adds is important: genuine creative edge requires maintaining a rigorous structural understanding of the underlying technology. Directing AI well is not a soft skill. It demands knowing the mechanics and limits of the tool you are steering — and that requirement will only intensify as the tools become more powerful.

PodArticle Watch original